BioSpace News Archive

Boston Scientific Corporation generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022 , after the market closes.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that it has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institute’s Division of Cancer Treatment and Diagnosis.

First Wave BioPharma, Inc. announced the formation of a clinical steering committee focused on advancing the Company’s inflammatory bowel disease product portfolio, including FW-UP, FW-UC and FW-CD.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP).

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that it has agreed to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer for gross proceeds of $25.0 million (the “Transaction”).

XRHealth, the gateway to the healthcare metaverse, announces today their virtual/augmented reality therapy is now available in the United States to treat patients with autism.

Deciphera Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share.

DUBAI, United Arab Emirates, Obese people are seldom prone to health implications arising from increasing caseload for varicose veins in their body.

The global healthcare IT market is expected to gain a valuation of US$ 880,688.75 Mn by 2030.